Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-826; MK-3475-826/KEYNOTE-826
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 14 Sep 2018 Planned initiation date changed from 26 Sep 2018 to 11 Oct 2018.
    • 24 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top